“While SAMe supplementation benefits in mood, joint, and liver health are established and continue to be reinforced through published data, scientific breakthroughs, and revolutionary approaches today explore for understanding SAMe’s role in long-term health and longevity through epigenetic regulation and methylation,” says Sophie Legrain-Raspaud, Gnosis Research & Application Director, explaining that Gnosis has long-standing relationships and open collaborations with research institutes to explore how SAMe is linked with human health. “Slowing or averting age-related declines in physical and cognitive health to promote anti-aging effects and longevity can be possible today by taking advantage of the state-of-the-art scientific approach. By going deep inside the mechanisms and the roles of naturally and multi-potent occurring substances like SAMe, we believe we can improve the chances of maintaining optimal health later in life.”
Chicory Root Fibers Selectively Increase Bifidobacteria Independent of Food Application and Matrix
Anke Sentko, Vice President Regulatory Affairs & Nutrition Communication at BENEO, said: “Thanks to this study, product developers can ‘tick off’ one key question from their checklist: does the functional ingredient deliver the desired benefit when used in the final application? And the answer for chicory root fiber enrichment clearly is ‘yes.’ It has now been scientifically proven that the intended Bifidobacteria growth is independent of the food matrix that is used. These findings add to the large body of studies about the beneficial effects of chicory root fibers that already exist and are based on more than 25 years of scientific research on the proven prebiotics inulin and oligofructose.”
BENEO’s chicory root fibers, Orafti Inulin and Oligofructose, are plant-based prebiotics, comply with the ISAPP (International Scientific Association for Probiotics and Prebiotics) definition of prebiotics, and are backed up by the highest level of scientific evidence established in more than 25 years of scientific research.
Sustainability Horizon Scan Report for EPA & DHA Industry
The Global Organization for EPA and DHA Omega-3s (GOED) commissioned a comprehensive sustainability report from sustainable food consultancy Tasting the Future. GOED explained that the "horizon scan" report explores more than 20 pivotal environmental, social and governance trends that may become increasingly important to the EPA and DHA omega-3 industry over the next decade. The goal: to help omega-3 businesses respond and inform their long-term decision-making and strategic thinking. The report can serve as a valuable tool to help identify future opportunities within international markets or prepare for and mitigate risks within evolving legislative, consumer, industry and technological landscapes, GEOD said. In addition, it offers a set of actionable recommendations and next steps for all stakeholders in the EPA+DHA omega-3 space. Download the report here.
Citrus flavonoid blend improves prediabetic microbiota
Ingredients by Nature announce the publication of its research investigating its patented citrus flavonoid blend Eriomin on prediabetic microbiota. Research The 12-week double-blind, randomized controlled clinical trial published in the Food Science & Nutrition Journal showed Eriomin can attenuate intestinal dysbiosis. Male and female volunteers with prediabetes, ages 30-69 years old, were given 200 mg/day of Eriomin or a placebo and instructed to maintain their usual diet. Two registered dietitians followed participants during the trial period, and blood and fecal samples were collected at the beginning and end of the study. The findings in the Eriomin group after 12 weeks of supplementation:
- reduced growth of Firmicutes – main microbiota phylum, typically found in high levels in prediabetic and obese individuals and associated with a carbohydrate-rich diet.
- decreased the abundance of the Lachnospiraceae family, which is linked to glycemic dysregulation, metabolic syndrome, excess weight and prediabetes.
- increased Ruminococcaceae family by 38%; these microorganisms produce short-chain fatty acids that can strengthen the intestinal barrier and support a healthy inflammatory response.
- positive correlation between Blautia and hyperglycemia, suggesting that Blautia depletion was associated with reduced blood glucose in patients treated with Eriomin.
- decreased fasting blood glucose by 6.5% and increased GLP-1 incretin by 22%; both results were statistically different from the placebo group (p<0.05).
“These results further demonstrate Eriomin’s potential for those who need support in maintaining healthy blood glucose levels,” said Rob Brewster, President of Ingredients by Nature. “This is the third published human clinical trial backing Eriomin. We are thrilled to share this news with the industry and will continue investigating Eriomin’s powerful effects for numerous health benefits.”